Portal de Periódicos da CAPES

Can Clinical Features Predict Tau Pathology in Patients with Behavioral Variant Frontotemporal Dementia (bvFTD)? (P05.101)

2013; Lippincott Williams & Wilkins; Volume: 80; Issue: 7_supplement Linguagem: Inglês

10.1212/wnl.80.7_supplement.p05.101

1526-632X

Katya Rascovsky, John R. Hodges, David S. Knopman, Mario F. Mendez, Joel H. Kramer, John Neuhaus, John C. van Swieten, Harro Seelaar, Elise G.P. Dopper, Chiadi U. Onyike, Argye E. Hillis, Keith A. Josephs, Bradley F. Boeve, Andrew Kertesz, William W. Seeley, Katherine Rankin, Julene K. Johnson, Maria Gorno Tempini, Howard J. Rosen, Caroline Latham, Albert Lee, Christopher Kipps, Patricia Lillo, Olivier Piguet, Jonathan D. Rohrer, Martin N. Rossor, Jason D. Warren, Nic Fox, Douglas Galasko, David P. Salmon, Sandra E. Black, M.‐Marsel Mesulam, Sandra Weıntraub, Bradford C. Dickerson, Janine Diehl, Florence Pasquier, Vincent Deramecourt, Florence Lebert, Yolande A.L. Pijnenburg, Tiffany W. Chow, Facundo Manes, Jordan Grafman, Stefano F. Cappa, Morris Freedman, Bruce L. Miller, Murray Grossman,

Neurological Disease Mechanisms and Treatments

OBJECTIVE: To determine whether clinical features predict tau pathology in behavioral variant frontotemporal dementia (bvFTD). BACKGROUND: Although characterized by behavior changes and frontotemporal atrophy, bvFTD is pathologically heterogeneous. With the development of tau agents for the treatment of FTD, it is increasingly important to establish underlying tau pathology during life. Therefore, we attempted to identify early clinical predictors of tau pathology in a multi-site sample of autopsy-confirmed bvFTD patients. DESIGN/METHODS: 146 cases from the International bvFTD Criteria Consortium (FTDC) database were included. Cases met Possible bvFTD criteria at presentation and had FTLD pathology at autopsy. Chi-squared analyses compared early behavioral and cognitive features in tau positive (tau+) and tau negative (non-tau) cases. RESULTS: 56 cases (38%) were classified as tau+ and 90 (62%) as non-tau. A higher proportion of non-tau cases presented with a neuropsychological profile consistent with bvFTD (i.e., executive/generation deficits with relative sparing of memory and visuospatial functions: tau+=69%, non-tau=84%, X2=4.1, p CONCLUSIONS: Our findings suggest that prediction of tau pathology in bvFTD may be difficult based on demographic, clinical or behavioral features alone. Accurate prediction of tau pathology in bvFTD may ultimately depend on more detailed cognitive/behavioral testing coupled with imaging and biofluid biomarkers. Supported by: AG17586, NS44266, P50-AG016574, P01-AG019724, P50-AG023501, CA DHS 07-65807. Disclosure: Dr. Rascovsky has nothing to disclose. Dr. Hodges has nothing to disclose. Dr. Knopman has received personal compensation for activities with Eli Lilly & Company. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from TauRx. Dr. Mendez has received personal compensation in an editorial capacity for UpToDate. Dr. Kramer has nothing to disclose. Dr. Neuhaus has nothing to disclose. Dr. Van Swieten has nothing to disclose. Dr. Seelaar has nothing to disclose. Dr. Dopper has nothing to disclose. Dr. Onyike has received research support from Forest Laboratories, Inc. Dr. Hillis has received personal compensation in an editorial capacity for Behavioural Neurology. Dr. Hillis has received research support from Allon Pharmaceutical. Dr. Josephs has nothing to disclose. Dr. Boeve has received research support from Cephalon, Inc.; Allon Therapeutics; and GE Healthcare. Dr. Kertesz has received personal compensation for activities with Pfizer and Janssen as a consultant. Dr. Kertsz has received research support from Sanofi and Janssen. Dr. Seeley has received personal compensation for activities with Korea Novartis, Summer Street Research Partners and Bristol-Myers Squibb for speaker, consulting and scientific advisory boards. Dr. Rankin has nothing to disclose. Dr. Johnson has nothing to disclose. Dr. Gorno Tempini has nothing to disclose. Dr. Rosen has nothing to disclose. Dr. Latham has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Kipps has nothing to disclose. Dr. Lillo has nothing to disclose. Dr. Piguet has nothing to disclose. Dr. Rohrer has nothing to disclose. Dr. Rossor has nothing to disclose. Dr. Warren has nothing to disclose. Dr. Fox has received personal compensation in an editorial capacity for Alxforum. Dr. Fox has received license fee payments from IXICO. Dr. Fox has received research support from Elan/Janssen Alzheimer Immunotherapy, Lundbeck Research USA, Inc., and Pfizer/Wyeth Pharmaceuticals. Dr. Galasko has received personal compensation for activities with United BioSource Corporation, Pfizer, Janssen, Elan Pharmaceuticals, Lundbeck, and Balance Pharma as a consultant. Dr. Galasko has received personal compensation in an editorial capacity for Alzheimer9s Disease Research and Treatment. Dr. Galasko has received research support from Pfizer and Eli Lilly, Inc. Dr. Salmon has received personal compensation for activities with Bristol Myer Squibb as consultant. Dr. Black has recieved personal compensation for activities with Novartis Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Pharmaceuticals, and Bristol-Myers Squibb, and Elan. Dr. Black has received research support from Novartis Pharmaceuticals, Pfizer, Roche, and GlaxoSmithKline. Dr. Mesulam has nothing to disclose. Dr. Weintraub has nothing to disclose. Dr. Dickerson has received personal compensation for activities with Pfizer Inc and En Vivo as a consultant. Dr. Diehl has nothing to disclose. Dr. Pasquier has nothing to disclose. Dr. Deramecourt has nothing to disclose. Dr. Lebert has nothing to disclose. Dr. Pijnenburg has nothing to disclose. Dr. Chow has received personal compensation for activities with Bristol-Myers Squibb Company as a consultant. Dr. Manes has nothing to disclose. Dr. Grafman has nothing to disclose. Dr. Cappa has received personal compensation in an editorial capacity for Behavioral Neurology. Dr. Freedman has been listed on a provisional patent related to methods and kits for differential diagnosis of Alzheimer9s disease vs frontotemporal dementia using blood biomarkers. Dr. Freedman has received research support from Lundbeck, Canada. Dr. Miller has received personal compensation for activities with Allon Therapeuctics, Inc. and TauRx Therapeutics, Ltd. Dr. Miller has received research support from Novartis. Dr. Grossman has nothing to disclose.